BlossomHill Therapeutics, Inc.: 5%+ holders

As of November 6, 2026, 4 holders' latest Schedule 13D or 13G filings report owning 5% or more of BlossomHill Therapeutics, Inc. The largest reported stake is Cormorant Asset Management, LP's, at 11.8%. 4 filings are on record since August 13, 2026 (Schedule 13D, August 13, 2026).

CARL GORDON is also named on 1 other Form D filing ↓

Sell to companies like BlossomHill Therapeutics, Inc? Enter your website and see 10 with a filed reason to buy from you this month. Free.

Your website Find my buyers

Opens in a new tab. No signup.

Key facts

• Filing 2026-08-18 · Reporting person: Orbimed Advisors LLC · Sole voting: 0 · Shared voting: 2,714,279 · Sole dispositive: 0 · Shared dispositive: 2,714,279 · SCHEDULE 13D, 2026-08-18
• Filing 2026-08-17 · Reporting person: Vivo Innovation Fund II Holdings, L.P. · Sole voting: 1,681,240 · Shared voting: 0 · Sole dispositive: 1,681,240 · Shared dispositive: 0 · SCHEDULE 13G, 2026-08-17
• Filing 2026-08-14 · Reporting person: Perceptive Advisors LLC · Sole voting: 0 · Shared voting: 1,808,533 · Sole dispositive: 0 · Shared dispositive: 1,808,533 · SCHEDULE 13G, 2026-08-14
• Filing 2026-08-13 · Reporting person: Cormorant Global Healthcare Master Fund, LP · Sole voting: 0 · Shared voting: 959,090 · Sole dispositive: 0 · Shared dispositive: 959,090 · SCHEDULE 13D, 2026-08-13

BlossomHill Therapeutics, Inc. has 4 Schedule 13D or 13G filings on record since 2026-08-13. 4 holders' latest filing reports 5% or more of common stock. Each figure below is the holder's own, as filed, with the filing linked.

Holders

Swipe the table sideways to see every column.

Holding shares or following this stake? See who's behind BlossomHill Therapeutics, Inc. and the warning signs.

See BlossomHill Therapeutics, Inc.'s free Snapshot Watch BlossomHill Therapeutics, Inc.: email me the next time it files something

Free to see. No signup.

Keep reading

More on BlossomHill Therapeutics, Inc. and the records around it.

The people at BlossomHill Therapeutics, Inc.

• CARL GORDON is also named on 1 other Form D filing: Avenzo Therapeutics, Inc. (Sep 2025)

BlossomHill Therapeutics, Inc. elsewhere on the record

• IPO filing Aug 2026
• Form D filing Dec 2025
• Who owns it

Companies that share a holder

• Cormorant Global Healthcare Master Fund, LP also filed stake reports on 17 other companies: Corbus Pharmaceuticals Holdings, Inc. (Nov 2026), Adlai Nortye Ltd. (Aug 2026), BioAge Labs, Inc. (Aug 2026)
• ORBIMED ADVISORS LLC also filed stake reports on 38 other companies: Aspen Neuroscience, Inc. (Nov 2026), ArriVent BioPharma, Inc. (Oct 2026), ADARx Pharmaceuticals, Inc. (Oct 2026)
• Perceptive Advisors LLC also filed stake reports on 57 other companies: Nautilus Biotechnology, Inc. (Nov 2026), Athira Pharma, Inc. (Oct 2026), IRulya Therapeutics Inc. (Oct 2026)

Want the whole picture on BlossomHill Therapeutics, Inc.?

Example from a real report (our sample on Target): “In March 2026, Target announced a planned incremental $1 billion operating investment” Source: Target Corporation (press release)

A Full Report on BlossomHill Therapeutics, Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.

What the Full Report on BlossomHill Therapeutics, Inc. covers

1. The Short Answer

2. Which Company This Is

3. What They Do, And How The Money Works

4. Who Runs It, And How To Reach Them

5. The Money: Funding, Valuation, Runway

6. Who Pays Them, And Who They Are Up Against

7. Warning Bells

8. Sources

   8 cited sources found

Plus the sections for what you are deciding, which you pick after ordering.

Order Full ReportSee a sample report

A real finished report, first screen. Opens in a new tab.

Voting and dispositive power, as filed

Swipe the table sideways to see every column.

The latest filing identifies BlossomHill Therapeutics, Inc. by CUSIP 095130100 and gives its principal executive office as 10255 Science Center Drive, Suite 200, San Diego, CA 92121 (SCHEDULE 13D, 2026-08-18).

Source of funds (Item 3)

Of the Common Stock reported herein as being beneficially owned by the Reporting Persons, 1,599,993 and 1,701,541 shares were issued upon the automatic conversion of shares of Series A Preferred Stock and Series B Preferred Stock, respectively, upon the closing of the Issuer's initial public offering on August 10, 2026. The shares of Series A Preferred Stock and Series B Preferred Stock were purchased in private sales for approximately $49,999,990.59 using working capital of the Reporting Persons.Cormorant Asset Management, LP, SCHEDULE 13D, 2026-08-13

In March 2021, OrbiMed Advisors and OrbiMed GP, pursuant to their authority under the limited partnership agreement of OrbiMed Private Investments VIII, LP ("OPI VIII"), as more particularly described in Item 6 below, caused OPI VIII to purchase 1,039,996 shares of Series A preferred stock, par value $0.001 per share of the Issuer ("Series A preferred stock").Orbimed Advisors LLC, SCHEDULE 13D, 2026-08-18

Purpose of Transaction (Item 4)

Cormorant Asset Management, LP

The Reporting Persons acquired the securities reported herein for the benefit of the above-referenced private investment funds and accounts for investment purposes. The Reporting Persons intend to evaluate this investment in the Issuer and options with respect to such investment on an ongoing basis. The Reporting Persons may acquire additional Common Stock of the Issuer from time to time or may dispose of any or all of such Common Stock or other securities held or beneficially owned by them at any time. From time to time, the Reporting Persons may engage in discussions with the Issuer's Board of Directors and/or members of the Issuer's management team concerning, without limitation, potential business combinations and strategic alternatives, the business, operations, capital structure, governance, management, strategy of the Issuer and other matters concerning the Issuer. The Reporting Persons reserve the right to change their purpose and to formulate and implement plans or proposals with respect to the Issuer at any time and from time to time. Any such action may be made by the Reporting Persons alone or in conjunction with other shareholders, potential acquirers, financing sources and/or other third parties and could include one or more purposes, plans or proposals that relate to or would result in actions required to be reported herein in accordance with Item 4 of Schedule 13D. Bihua Chen, who serves as the manager of Cormorant Asset Management, LP, Cormorant …The first part of Item 4 of the SCHEDULE 13D filed 2026-08-13; the filing has the rest

Orbimed Advisors LLC

This Statement on Schedule 13D relates to the acquisition of Shares by the Reporting Persons. The Shares acquired by the Reporting Persons were acquired for the purpose of making an investment in the Issuer and not with the intention of acquiring control of the Issuer's business on behalf of the Reporting Persons' respective advisory clients. The Reporting Persons from time to time intend to review their investment in the Issuer on the basis of various factors, including the Issuer's business, financial condition, results of operations and prospects, general economic and industry conditions, the securities markets in general and those for the Issuer's Shares in particular, as well as other developments and other investment opportunities. Based upon such review, the Reporting Persons will take such actions in the future as the Reporting Persons may deem appropriate in light of the circumstances existing from time to time. If the Reporting Persons believe that further investment in the Issuer is attractive, whether because of the market price of Shares or otherwise, they may acquire Shares or other securities of the Issuer either in the open market or in privately negotiated transactions. Similarly, depending on market and other factors, the Reporting Persons may determine to dispose of some or all of the Shares currently owned by the Reporting Persons or otherwise acquired by the Reporting Persons either in the open market or in privately negotiated transactions. Except as …The first part of Item 4 of the SCHEDULE 13D filed 2026-08-18; the filing has the rest

Timeline

Swipe the table sideways to see every column.

Questions about who owns BlossomHill Therapeutics, Inc.

Who owns BlossomHill Therapeutics, Inc.?

On this page, 4 holders' latest ownership filings report 5% or more of BlossomHill Therapeutics, Inc.: Cormorant Asset Management, LP (11.8%, Schedule 13D, filed 2026-08-13), Orbimed Advisors LLC (8.9%, Schedule 13D, filed 2026-08-18), Perceptive Advisors LLC (5.9%, Schedule 13G, filed 2026-08-14) and Vivo Innovation Fund II Holdings, L.P. (5.5%, Schedule 13G, filed 2026-08-17).

Who are the largest shareholders of BlossomHill Therapeutics, Inc.?

By the share each holder's latest filing reports, the largest holders of BlossomHill Therapeutics, Inc. on this page are Cormorant Asset Management, LP (11.8%), Orbimed Advisors LLC (8.9%) and Perceptive Advisors LLC (5.9%).

When did Cormorant Asset Management, LP buy into BlossomHill Therapeutics, Inc.?

The filings give report dates, not purchase dates. The earliest filing from Cormorant Asset Management, LP on this page is the Schedule 13D, filed 2026-08-13, reporting 11.8%.

Is this an audit or a full list?

Neither. The ownership list on this page covers only Schedule 13D and 13G filings, which holders make once they own 5% or more of a class of shares (an amendment can report a stake that has since fallen below 5%); 4 such filings are shown here. It is not an audit and not a full cap table: holders who never reached 5% are not listed, and a stake can change after its latest filing.

Also on the record for BlossomHill Therapeutics, Inc.

Swipe the table sideways to see every column.

Tools for this story

Each opens in a new tab, filled in for BlossomHill Therapeutics, Inc.. With no account yet, you sign up free and land on the result.

• Get an alert when BlossomHill Therapeutics, Inc. is mentioned again
• Find former BlossomHill Therapeutics, Inc. employees to interview
• Verify a claim or statistic

Where this comes from

Anyone who comes to own more than 5% of a class of a listed company's voting shares has to tell the SEC. A holder who may seek to change or influence the company files Schedule 13D, and has to say in Item 4, "Purpose of Transaction", what it intends to do. A holder with no such intent, such as many index and passive funds, may file the shorter Schedule 13G. Both are amended when the stake changes, including when it falls below 5%.

Every row here is one of those filings, linked to the filing itself. Percentages and share counts are exactly as the holder filed them, for the holder the filing names; an amendment showing a lower figure is shown as filed. Item 4 text is quoted word for word. Where a 13D's Item 4 contains a sentence stating a definite intent to influence the company, that sentence is marked and quoted; the page does not describe the holder or its motives beyond the words it filed. Nothing here is investment advice.

All recent stakesThat week's stakes